Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 31

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 31
---
 have four years to comply with the requirements from the later of: (i) December 10, 2024 (the date the policy was amended) and (ii) their appointment or election to the board or as a named executive officer, as applicable. The stock ownership guidelines are summarized below:

| Category                 | ​ | ​ | Requirement           | ​ | ​ | Phase-In Window | ​ |
| Chief Executive Officer  | ​ | ​ | 6x Annual Base Salary | ​ | ​ | 5 Years         | ​ |
| Named Executive Officers | ​ | ​ | 3x Annual Base Salary | ​ | ​ | 5 Years         | ​ |
| Non-Employee Directors   | ​ | ​ | 5x Annual Retainer    | ​ | ​ | 4 Years         | ​ |

Equity included in the measurement of compliance is comprised of beneficial ownership of: (i) common stock held, (ii) unvested restricted stock or restricted stock units subject to time-based vesting, and (iii) common stock held through any Company-sponsored plan. Guideline attainment is measured using the 30-day average closing price of the Company’s common stock on July 30 th of each year. If an individual is not compliant within the phase-in period, they are expected to retain at least 50% of the net after-tax shares of common stock acquired through stock option exercises or restricted stock unit vesting until the guideline is met. Once the guideline is attained, the individual is deemed to be compliant irrespective of changes in the price of the Company’s common stock unless they sell those shares. In 2024, all current named executive officers and non-employee directors were compliant with the stock ownership guidelines or were within the phase-in period.

40 | investor.pacira.com

TABLE OF CONTENTS

| ​ | ​ | AUDITMATTERS | ​ |

| ​ | ​                           | ​ | ​ | ​                                   | ​ | ​ |              | ​ | ​ | ​                 | ​ | ​ | ​                     | ​ | ​ | ​                         | ​ | ​ | ​                                           | ​ | ​ | ​                     | ​ | ​ | ​          | ​ | ​ | ​          | ​ |
| ​ | 2025PROXY STATEMENT SUMMARY | ​ | ​ | CORPORATEGOVERNANCEAND BOARDMATTERS | ​ | ​ | AUDITMATTERS | ​ | ​ | EXECUTIVEOFFICERS | ​ | ​ | EXECUTIVECOMPENSATION |